Loading...

Atara Biotherapeutics

DB:AT2
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AT2
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
  • Atara Biotherapeutics has significant price volatility in the past 3 months.
AT2 Share Price and Events
7 Day Returns
-14.5%
DB:AT2
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-11.7%
DB:AT2
-9.2%
DE Biotechs
-6.7%
DE Market
AT2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Atara Biotherapeutics (AT2) -14.5% -18.9% -13.7% -11.7% 53.1% -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • AT2 underperformed the Biotechs industry which returned -9.2% over the past year.
  • AT2 underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
AT2
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Atara Biotherapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Atara Biotherapeutics. This is due to cash flow or dividend data being unavailable. The share price is €28.11.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Atara Biotherapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Atara Biotherapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AT2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-5.27
NasdaqGS:ATRA Share Price ** NasdaqGS (2019-04-18) in USD $31.86
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Atara Biotherapeutics.

DB:AT2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ATRA Share Price ÷ EPS (both in USD)

= 31.86 ÷ -5.27

-6.05x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atara Biotherapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Atara Biotherapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Atara Biotherapeutics's expected growth come at a high price?
Raw Data
DB:AT2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.05x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
20.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Atara Biotherapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Atara Biotherapeutics's assets?
Raw Data
DB:AT2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $7.37
NasdaqGS:ATRA Share Price * NasdaqGS (2019-04-18) in USD $31.86
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:AT2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ATRA Share Price ÷ Book Value per Share (both in USD)

= 31.86 ÷ 7.37

4.32x

* Primary Listing of Atara Biotherapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atara Biotherapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Atara Biotherapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Atara Biotherapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Atara Biotherapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Atara Biotherapeutics expected to grow at an attractive rate?
  • Atara Biotherapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Atara Biotherapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Atara Biotherapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:AT2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:AT2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 20.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AT2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AT2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 403 215 15 3
2022-12-31 258 103 -182 3
2021-12-31 79 -29 -278 4
2020-12-31 31 -213 -291 4
2019-12-31 0 -256 -301 6
DB:AT2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -180 -231
2018-09-30 -147 -186
2018-06-30 -119 -159
2018-03-31 -100 -135
2017-12-31 -88 -119
2017-09-30 -84 -102
2017-06-30 -79 -97
2017-03-31 -70 -88
2016-12-31 -60 -79
2016-09-30 -50 -82
2016-06-30 -48 -69
2016-03-31 -43 -65

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Atara Biotherapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Atara Biotherapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AT2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Atara Biotherapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AT2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.29 2.46 -2.00 3.00
2022-12-31 -2.80 -2.54 -3.05 2.00
2021-12-31 -3.48 -1.46 -4.50 3.00
2020-12-31 -5.32 -4.09 -6.18 4.00
2019-12-31 -6.13 -5.79 -6.60 5.00
DB:AT2 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -5.27
2018-09-30 -4.65
2018-06-30 -4.37
2018-03-31 -4.16
2017-12-31 -4.00
2017-09-30 -3.48
2017-06-30 -3.33
2017-03-31 -3.05
2016-12-31 -2.75
2016-09-30 -2.87
2016-06-30 -2.42
2016-03-31 -2.37

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Atara Biotherapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Atara Biotherapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Atara Biotherapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Atara Biotherapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Atara Biotherapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Atara Biotherapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Atara Biotherapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Atara Biotherapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Atara Biotherapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Atara Biotherapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AT2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -230.70 69.65 167.46
2018-09-30 -186.00 61.12 129.97
2018-06-30 -158.74 55.32 107.22
2018-03-31 -135.28 45.70 92.13
2017-12-31 -119.49 40.33 81.21
2017-09-30 -102.41 34.58 69.91
2017-06-30 -96.69 30.65 68.11
2017-03-31 -88.14 27.53 62.81
2016-12-31 -79.05 24.73 56.51
2016-09-30 -82.06 24.99 59.27
2016-06-30 -68.56 21.99 48.58
2016-03-31 -64.62 19.10 47.10
2015-12-31 -57.22 16.83 41.62
2015-09-30 -46.50 16.84 30.44
2015-06-30 -40.55 14.40 26.56
2015-03-31 -30.12 12.16 18.23
2014-12-31 -28.01 12.71 15.45
2014-09-30 -21.04 8.33 12.65
2014-06-30 -17.65 7.49 10.09
2014-03-31 -14.52 6.92 7.49
2013-12-31 -8.77 3.76 4.86
2012-12-31 -12.33 2.50 0.72

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Atara Biotherapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Atara Biotherapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Atara Biotherapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Atara Biotherapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Atara Biotherapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Atara Biotherapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Atara Biotherapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Atara Biotherapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Atara Biotherapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Atara Biotherapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 29.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Atara Biotherapeutics Company Filings, last reported 3 months ago.

DB:AT2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 338.86 10.90 309.63
2018-09-30 403.05 10.30 364.54
2018-06-30 452.50 10.30 417.02
2018-03-31 439.18 10.30 407.32
2017-12-31 177.86 0.50 166.10
2017-09-30 205.96 0.00 200.22
2017-06-30 221.14 0.00 216.90
2017-03-31 233.13 0.00 230.65
2016-12-31 253.74 0.00 255.68
2016-09-30 270.20 0.00 278.15
2016-06-30 290.25 0.00 294.56
2016-03-31 303.83 0.00 306.40
2015-12-31 315.10 0.00 320.48
2015-09-30 333.75 0.00 334.27
2015-06-30 149.26 0.00 155.03
2015-03-31 166.09 0.00 166.70
2014-12-31 103.18 0.00 104.12
2014-09-30 51.54 0.00 51.70
2014-06-30 56.22 0.00 56.50
2014-03-31 59.87 0.00 62.03
2013-12-31 50.07 0.00 51.62
2012-12-31 2.98 0.00 4.21
  • Atara Biotherapeutics's level of debt (3.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 3.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Atara Biotherapeutics has sufficient cash runway for 1.4 years based on current free cash flow.
  • Atara Biotherapeutics has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 56.9% each year.
X
Financial health checks
We assess Atara Biotherapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Atara Biotherapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Atara Biotherapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Atara Biotherapeutics dividends. Estimated to be 1.57% next year.
If you bought €2,000 of Atara Biotherapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Atara Biotherapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Atara Biotherapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AT2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AT2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 1.00 2.00
2020-12-31 0.50 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Atara Biotherapeutics has not reported any payouts.
  • Unable to verify if Atara Biotherapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Atara Biotherapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Atara Biotherapeutics has not reported any payouts.
Future Payout to shareholders
  • The company is expected to pay a dividend in 3 years whilst incurring a loss, therefore the dividend is not expected to be well covered.
X
Income/ dividend checks
We assess Atara Biotherapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Atara Biotherapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Atara Biotherapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Atara Biotherapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Isaac Ciechanover
COMPENSATION $3,366,822
AGE 47
TENURE AS CEO 6.7 years
CEO Bio

Dr. Isaac E. Ciechanover, M.D., has been the President and Chief Executive Officer of Atara Biotherapeutics, Inc. since August 2012. Dr. Ciechanover serves as the President of Pinta Biotherapeutics, Inc. For more than 15 years, Dr. Ciechanover has worked with entrepreneurs and organizations to advance the practice of medicine through innovation and technology. With both a medical and business background, he bridges the gap between the scientific and business communities. He was an Investment Partner at Kleiner Perkins Caufield & Byers. He joined Kleiner, Perkins, Caufield & Byers in April 2010 and provided counsel and guidance to its network of life science entrepreneurs. Dr. Ciechanover was an Associate at FirstMark Capital, L.L.C. He served as the Executive Director of Business Development at Celgene Corporation. Dr. Ciechanover’s responsibilities included sourcing and execution and leading global teams for in-licensing and merger and acquisition activities for the research and development and commercial functions. He was also the Global Project Leader for Celgene Corporation’s first clinical stage biologic therapy and initiated and led its clinical, venture investment and alliance management activities. Dr. Ciechanover managed business development and planning for Amylin Pharmaceuticals. He also analyzed and vetted acquisition candidates at Pfizer Inc. He serves as a Director of Atara Biotherapeutics, Inc. and Pinta Biotherapeutics, Inc. Dr. Ciechanover drove life sciences venture capital efforts for Pequot Ventures. He began his career working as a venture capitalist in the healthcare practice of Pequot Ventures. He has sourced a number of investments for Pequot Ventures and is a board observer at Corventis, Crescendo, Elcelyx, Five Prime and Tesaro. Dr. Ciechanover is a contributor to the Multiple Myeloma Research Foundation and Project Smile. He received an M.D. from the Weill Cornell Medical College; an M.B.A. from the Harvard Business School; an M.Phil in Epidemiology from the University of Cambridge; and a B.A. in Psychology from Stanford University.

CEO Compensation
  • Isaac's compensation has been consistent with company performance over the past year.
  • Isaac's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Atara Biotherapeutics management team in years:

2
Average Tenure
47
Average Age
  • The average tenure for the Atara Biotherapeutics management team is less than 2 years, this suggests a new team.
Management Team

Isaac Ciechanover

TITLE
President
COMPENSATION
$3M
AGE
47
TENURE
6.7 yrs

Joe Newell

TITLE
Executive VP & Chief Technical Operations Officer
COMPENSATION
$2M
AGE
48
TENURE
2 yrs

Derrell Porter

TITLE
Senior VP & Global Commercial Head
COMPENSATION
$2M
AGE
47
TENURE
1.9 yrs

Utpal Koppikar

TITLE
Chief Financial Officer
TENURE
0.8 yrs

Chris Haqq

TITLE
Executive VP of R&D & Chief Scientific Officer
COMPENSATION
$3M
AGE
52
TENURE
6.6 yrs

John Craighead

TITLE
Vice President of Investor Relations & Corporate Communications

Mina Kim

TITLE
Senior VP & General Counsel
AGE
44
TENURE
1 yrs

Steve Bertram

TITLE
Senior Vice President of Global Human Resources
TENURE
2.7 yrs

AJ Joshi

TITLE
Chief Medical Officer

Dietmar Berger

TITLE
Global Head of Research and Development
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the Atara Biotherapeutics board of directors in years:

4.6
Average Tenure
53
Average Age
  • The tenure for the Atara Biotherapeutics board of directors is about average.
Board of Directors

Carol Gallagher

TITLE
Chairman & Lead Independent Director
COMPENSATION
$345K
AGE
53

Isaac Ciechanover

TITLE
President
COMPENSATION
$3M
AGE
47
TENURE
6.7 yrs

Beth Seidenberg

TITLE
Director
COMPENSATION
$323K
AGE
61
TENURE
6.7 yrs

Matt Fust

TITLE
Director
COMPENSATION
$338K
AGE
53
TENURE
5.1 yrs

Eric Dobmeier

TITLE
Director
COMPENSATION
$330K
AGE
49
TENURE
4.1 yrs

Bill Heiden

TITLE
Director
COMPENSATION
$323K
AGE
58
TENURE
3.4 yrs

Roy Baynes

TITLE
Director
AGE
63
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • Atara Biotherapeutics insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
19. Mar 19 Sell Alexandria Equities, LLC Company 15. Mar 19 15. Mar 19 -20,000 €33.78 €-675,648
01. Mar 19 Sell Joel Marcus Individual 28. Feb 19 28. Feb 19 -90 €31.67 €-2,851
08. Nov 18 Sell Joel Marcus Individual 07. Nov 18 07. Nov 18 -10,000 €31.68 €-316,827
08. Nov 18 Sell Carol Gallagher Individual 07. Nov 18 07. Nov 18 -21,374 €31.71 €-677,744
11. Sep 18 Buy Utpal Koppikar Individual 27. Jul 18 27. Jul 18 2,000 €31.58 €63,164
17. May 18 Sell Matthew Fust Individual 14. May 18 14. May 18 -12,286 €36.40 €-447,244
X
Management checks
We assess Atara Biotherapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Atara Biotherapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Details
Name: Atara Biotherapeutics, Inc.
AT2
Exchange: DB
Founded: 2012
$1,337,911,060
46,161,657
Website: http://www.atarabio.com
Address: Atara Biotherapeutics, Inc.
611 Gateway Boulevard,
Suite 900,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ATRA Common Stock Nasdaq Global Select US USD 17. Oct 2014
DB AT2 Common Stock Deutsche Boerse AG DE EUR 17. Oct 2014
LSE 0HIY Common Stock London Stock Exchange GB USD 17. Oct 2014
Number of employees
Current staff
Staff numbers
311
Atara Biotherapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:13
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/03
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.